Abstract
Background: Hepatocellular carcinoma (HCC) represents the most common malignant liver tumor in humans, which incidence and mortality have increased in Europe and United States in the last years. Most patients are diagnosed at an advanced stage, when it is not amenable to curative therapies, so there is an urgent need for new, more effective therapeutic tools and strategies. The molecular mechanisms of hepatocarinogenesis and HCC progression have been increasingly understood with intense research in recent years.
Methods: The goal of this work is to discuss the different signalling pathways as important potential therapeutic targets. Results: Disruption of pathways known to play roles in HCC, such as Wnt/β-catenin, Hedgehog, RAF/MEK/ERK, tryosine kinase receptor-related pathway, Met-HGF, VEGF/ VEGF and ROR signalling pathways may be seminal for liver oncogenesis. Conclusion: This review reveals that oncogenes, especially microRNAs that are conserved across species and interfere with signalling pathways might be used as promising strategies for halting or reversing the progression of HCC.Keywords: Hepatocellular carcinoma, hepatocarcinogenesis, genomics, signalling pathway, drug targets, microRNA.
Current Pharmaceutical Design
Title:Targeting Signalling Pathways in Hepatocellular Carcinoma
Volume: 23 Issue: 1
Author(s): Kaja Blagotinsek and Damjana Rozman
Affiliation:
Keywords: Hepatocellular carcinoma, hepatocarcinogenesis, genomics, signalling pathway, drug targets, microRNA.
Abstract: Background: Hepatocellular carcinoma (HCC) represents the most common malignant liver tumor in humans, which incidence and mortality have increased in Europe and United States in the last years. Most patients are diagnosed at an advanced stage, when it is not amenable to curative therapies, so there is an urgent need for new, more effective therapeutic tools and strategies. The molecular mechanisms of hepatocarinogenesis and HCC progression have been increasingly understood with intense research in recent years.
Methods: The goal of this work is to discuss the different signalling pathways as important potential therapeutic targets. Results: Disruption of pathways known to play roles in HCC, such as Wnt/β-catenin, Hedgehog, RAF/MEK/ERK, tryosine kinase receptor-related pathway, Met-HGF, VEGF/ VEGF and ROR signalling pathways may be seminal for liver oncogenesis. Conclusion: This review reveals that oncogenes, especially microRNAs that are conserved across species and interfere with signalling pathways might be used as promising strategies for halting or reversing the progression of HCC.Export Options
About this article
Cite this article as:
Blagotinsek Kaja and Rozman Damjana, Targeting Signalling Pathways in Hepatocellular Carcinoma, Current Pharmaceutical Design 2017; 23 (1) . https://dx.doi.org/10.2174/1381612822666161006160005
DOI https://dx.doi.org/10.2174/1381612822666161006160005 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reversing Breast Cancer Stem Cell into Breast Somatic Stem Cell
Current Pharmaceutical Biotechnology Harnessing Impaired Energy Metabolism in Cancer Cell: Small Molecule- Mediated Ways to Regulate Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry Applications of the Rare Earth Elements in Cancer Imaging and Therapy
Current Nanoscience Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry New Insights in Mast Cell Modulation by Palmitoylethanolamide
CNS & Neurological Disorders - Drug Targets 3-Hydroxy-2-phenyl-4(1H)-quinolinones as Promising Biologically Active Compounds
Mini-Reviews in Medicinal Chemistry Hybrid Compounds & Oxidative Stress Induced Apoptosis in Cancer Therapy
Current Medicinal Chemistry Nanomedicine: A New Frontier in Cancer Therapeutics
Current Drug Delivery Natural Killer Cells Preferentially Target Cancer Stem Cells; Role of Monocytes in Protection Against NK Cell Mediated Lysis of Cancer Stem Cells
Current Drug Delivery Editorial (Thematic Issue: Cytochrome P450 for Cancer Prevention and Therapy)
Anti-Cancer Agents in Medicinal Chemistry Human Immunodeficiency Virus-Associated Malignancies: A Therapeutic Update
Current HIV Research Targeting Glioblastoma Stem Cells: Cell Surface Markers
Current Medicinal Chemistry Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Interaction of Tumor Suppressor p53 with DNA and Proteins
Current Pharmaceutical Biotechnology Structure-Activity Relationship Studies on Holy Basil (Ocimum sanctum L.) Based Flavonoid Orientin and its Analogue for Cytotoxic Activity in Liver Cancer Cell Line HepG2
Combinatorial Chemistry & High Throughput Screening Antioxidant, Pro-Oxidant and Other Biological Activities of Sesquiterpenes
Current Topics in Medicinal Chemistry Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes
Current Pharmaceutical Design Fetuin-A: A Multifunctional Protein
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Bladder Cancer and Stem Cells
Current Signal Transduction Therapy A 1536-Well Fluorescence Polarization Assay to Screen for Modulators of the MUSASHI Family of RNA-Binding Proteins
Combinatorial Chemistry & High Throughput Screening